

Maklumat tambahan indikasi untuk upload pada laman web

Year 2012

Products Approved For Additional Indication (DCA 248 – 19 JANUARY 2012)

NO	PRODUCT (ACTIVE INGREDIENT)	ADDITIONAL INDICATION	MARKETING AUTHORIZATION HOLDER
1. 1.1	Afinitor 5mg Tablet (Everolimus 5mg)	<p><i>Afinitor is indicated for the treatment of progressive neuroendocrine tumours of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease.</i></p> <p><i>The safety and effectiveness of Afinitor in the treatment of patients with carcinoid tumours have not been established.</i></p>	<p><b>NOVARTIS CORPORATION (MALAYSIA) SDN. BHD.</b> Level 15, Crest, 3 Two Square No. 2, Jalan 19/1, 46300 Petaling Jaya, Selangor.</p>
1.2	Afinitor 10mg Tablet (Everolimus 10mg)	<p><u>Posology:</u> <i>The recommended dose of Afinitor for treatment of advanced pancreatic neuroendocrine tumour is 10 mg, to be taken once daily.</i></p>	